Suppr超能文献

相似文献

1
Cirrhotic cardiomyopathy.
Hepatol Int. 2009 Mar;3(1):294-304. doi: 10.1007/s12072-008-9109-7. Epub 2008 Nov 11.
2
[Cardiomyopathy in liver cirrhosis--an undiagnosed entity?].
Rev Med Chir Soc Med Nat Iasi. 2010 Apr-Jun;114(2):319-26.
3
Cirrhotic cardiomyopathy: review of pathophysiology and treatment.
Hepatol Int. 2014 Jul;8(3):308-15. doi: 10.1007/s12072-014-9531-y.
4
Therapy insight: Cirrhotic cardiomyopathy.
Nat Clin Pract Gastroenterol Hepatol. 2006 Jun;3(6):329-37. doi: 10.1038/ncpgasthep0498.
5
Cirrhotic cardiomyopathy.
Orphanet J Rare Dis. 2007 Mar 27;2:15. doi: 10.1186/1750-1172-2-15.
6
Cirrhotic cardiomyopathy.
J Hepatol. 2010 Jul;53(1):179-90. doi: 10.1016/j.jhep.2010.02.023. Epub 2010 Mar 31.
7
Cardiac dysfunction in cirrhosis.
Best Pract Res Clin Gastroenterol. 2007;21(1):125-40. doi: 10.1016/j.bpg.2006.06.003.
8
Cirrhotic cardiomyopathy.
Ann Hepatol. 2006 Jul-Sep;5(3):132-9.
9
Cirrhotic cardiomyopathy: Implications for the perioperative management of liver transplant patients.
World J Hepatol. 2015 Mar 27;7(3):507-20. doi: 10.4254/wjh.v7.i3.507.

引用本文的文献

2
Sound waves and solutions: Point-of-care ultrasonography for acute kidney injury in cirrhosis.
World J Crit Care Med. 2024 Jun 9;13(2):91212. doi: 10.5492/wjccm.v13.i2.91212.
4
Hepatorenal Syndrome-Novel Insights into Diagnostics and Treatment.
Int J Mol Sci. 2023 Dec 14;24(24):17469. doi: 10.3390/ijms242417469.
5
Recent advances in pathophysiology, diagnosis and management of hepatorenal syndrome: A review.
World J Hepatol. 2023 Jun 27;15(6):741-754. doi: 10.4254/wjh.v15.i6.741.
6
Value of red blood cell distribution width in prediction of diastolic dysfunction in cirrhotic cardiomyopathy.
World J Gastroenterol. 2023 Apr 21;29(15):2322-2335. doi: 10.3748/wjg.v29.i15.2322.
7
Cirrhotic Cardiomyopathy: The Interplay Between Liver and Heart.
Cureus. 2022 Aug 13;14(8):e27969. doi: 10.7759/cureus.27969. eCollection 2022 Aug.
9
Cardiac risk stratification of the liver transplant candidate: A comprehensive review.
World J Transplant. 2022 Jul 18;12(7):142-156. doi: 10.5500/wjt.v12.i7.142.

本文引用的文献

1
The endocannabinoid system and liver diseases.
J Neuroendocrinol. 2008 May;20 Suppl 1:47-52. doi: 10.1111/j.1365-2826.2008.01679.x.
2
Nuclear factor-kappaB inhibition improves myocardial contractility in rats with cirrhotic cardiomyopathy.
Liver Int. 2008 May;28(5):640-8. doi: 10.1111/j.1478-3231.2008.01692.x. Epub 2008 Mar 11.
3
Cirrhotic cardiomyopathy.
Semin Liver Dis. 2008 Feb;28(1):59-69. doi: 10.1055/s-2008-1040321.
4
Effect of chronic beta-blockade on QT interval in patients with liver cirrhosis.
J Hepatol. 2008 Mar;48(3):415-21. doi: 10.1016/j.jhep.2007.11.012. Epub 2007 Dec 26.
5
Cardiovascular complications of cirrhosis.
Gut. 2008 Feb;57(2):268-78. doi: 10.1136/gut.2006.112177.
6
Intracardiac and intrarenal renin-angiotensin systems: mechanisms of cardiovascular and renal effects.
J Investig Med. 2007 Nov;55(7):341-59. doi: 10.2310/6650.2007.00020.
7
Endocannabinoids acting at CB1 receptors mediate the cardiac contractile dysfunction in vivo in cirrhotic rats.
Am J Physiol Heart Circ Physiol. 2007 Sep;293(3):H1689-95. doi: 10.1152/ajpheart.00538.2007. Epub 2007 Jun 8.
8
QT interval analysis in patients with chronic liver disease: a prospective study.
Angiology. 2007 Apr-May;58(2):218-24. doi: 10.1177/0003319707300368.
9
Aldosterone as a cardiovascular risk hormone.
Endocr J. 2007 Jun;54(3):359-70. doi: 10.1507/endocrj.kr-80. Epub 2007 Apr 3.
10
The myocardial response to adrenomedullin involves increased cAMP generation as well as augmented Akt phosphorylation.
Peptides. 2007 Apr;28(4):900-9. doi: 10.1016/j.peptides.2007.01.011. Epub 2007 Jan 23.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验